Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CERSNASDAQ:NVCNNASDAQ:NYXHNASDAQ:STIM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCERSCerus$1.47+1.0%$1.35$1.12▼$2.54$280.05M1.561.37 million shs90,134 shsNVCNNeovasc$30.03$29.69$4.59▼$30.07$82.28M1.756,993 shs1 shsNYXHNyxoah$7.92+0.8%$7.28$5.55▼$11.87$269.76M1.62104,019 shs2,752 shsSTIMNeuronetics$3.42+1.5%$3.91$0.52▼$5.92$225.10M1.851.21 million shs148,165 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCERSCerus-3.33%+2.84%-3.97%+18.85%-14.71%NVCNNeovasc0.00%0.00%0.00%0.00%0.00%NYXHNyxoah+1.16%+5.08%+2.48%+29.70%+0.48%STIMNeuronetics-1.03%-3.44%-9.41%+1.51%+83.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCERSCerus3.34 of 5 stars3.54.00.00.03.41.70.6NVCNNeovascN/AN/AN/AN/AN/AN/AN/AN/ANYXHNyxoahN/AN/AN/AN/AN/AN/AN/AN/ASTIMNeuronetics1.6249 of 5 stars3.32.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCERSCerus 3.00Buy$3.50138.91% UpsideNVCNNeovasc 0.00N/AN/AN/ANYXHNyxoah 3.00Buy$14.5083.08% UpsideSTIMNeuronetics 2.67Moderate Buy$5.5060.82% UpsideCurrent Analyst Ratings BreakdownLatest NVCN, NYXH, CERS, and STIM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025NYXHNyxoahStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.004/8/2025NYXHNyxoahHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCERSCerus$185.14M1.51N/AN/A$0.31 per share4.73NVCNNeovasc$3.81M21.60N/AN/A$5.77 per share5.20NYXHNyxoah$4.89M55.16N/AN/A$3.60 per share2.20STIMNeuronetics$74.89M3.01N/AN/A$0.57 per share6.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCERSCerus-$20.92M-$0.10N/AN/AN/A-10.23%-34.81%-9.68%7/30/2025 (Estimated)NVCNNeovasc-$41.20M-$15.08N/A∞N/A-1,082.92%-127.25%-80.31%N/ANYXHNyxoah-$64.10M-$2.13N/AN/AN/A-1,571.39%-63.37%-46.67%8/5/2025 (Estimated)STIMNeuronetics-$43.71M-$1.31N/AN/AN/A-53.67%-174.15%-38.41%8/11/2025 (Estimated)Latest NVCN, NYXH, CERS, and STIM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025NYXHNyxoah-$0.60N/AN/AN/A$1.33 millionN/A5/14/2025Q1 2025NYXHNyxoah-$0.49-$0.63-$0.14-$0.63$1.64 million$1.12 million5/6/2025Q1 2025STIMNeuronetics-$0.13-$0.21-$0.08-$0.21$29.07 million$31.98 million5/1/2025Q1 2025CERSCerus-$0.05-$0.04+$0.01-$0.04$47.44 million$43.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCERSCerusN/AN/AN/AN/AN/ANVCNNeovascN/AN/AN/AN/AN/ANYXHNyxoahN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCERSCerus1.152.321.63NVCNNeovasc0.802.962.85NYXHNyxoah0.223.593.35STIMNeuronetics1.402.442.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCERSCerus78.37%NVCNNeovasc1.64%NYXHNyxoahN/ASTIMNeuronetics53.59%Insider OwnershipCompanyInsider OwnershipCERSCerus5.60%NVCNNeovascN/ANYXHNyxoahN/ASTIMNeuronetics9.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCERSCerus290191.16 million184.66 millionOptionableNVCNNeovasc492.74 millionN/ANot OptionableNYXHNyxoah11034.06 millionN/ANot OptionableSTIMNeuronetics18065.82 million59.37 millionOptionableNVCN, NYXH, CERS, and STIM HeadlinesRecent News About These CompaniesAssenagon Asset Management S.A. Acquires Shares of 97,656 Neuronetics, Inc. (NASDAQ:STIM)June 20, 2025 | marketbeat.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 19, 2025 | globenewswire.comNeuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook's Personalized Care Trial ProgramJune 10, 2025 | globenewswire.comNeuronetics, Inc. to Join Russell 3000® and Russell 2000® Indexes Effective June 30, 2025June 3, 2025 | nasdaq.comNeuronetics to join Russell 3000 and Russell 2000 indexesJune 2, 2025 | msn.comNeuronetics Set to Join Russell 2000® and Russell 3000® IndexesJune 2, 2025 | globenewswire.comNeuronetics, Inc. (NASDAQ:STIM) EVP Sells $826,074.20 in StockMay 15, 2025 | insidertrades.comNeuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness MonthMay 14, 2025 | tmcnet.comNeuronetics Announces Inducement Awards for New Team MembersMay 10, 2025 | msn.comNeuronetics, Inc. (NASDAQ:STIM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$6.83May 9, 2025 | finance.yahoo.comEarnings call transcript: Neuronetics Q1 2025 misses EPS, stock drops 22%May 7, 2025 | investing.comNeuronetics Reports 84% Revenue Growth in Q1 2025 Driven by Greenbrook AcquisitionMay 7, 2025 | nasdaq.comNeuronetics Reports 84% Revenue Growth in Q1 2025 Driven by Greenbrook AcquisitionMay 7, 2025 | nasdaq.comNeuronetics Inc (STIM) Q1 2025 Earnings Call Highlights: Revenue Surge Amidst Margin ChallengesMay 7, 2025 | finance.yahoo.comNeuronetics, Inc. (STIM) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comNeuronetics (STIM) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comNeuronetics Reports First Quarter 2025 Financial and Operating ResultsMay 6, 2025 | globenewswire.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 5, 2025 | globenewswire.comWhy Neuronetics, Inc. (STIM) is Surging in 2025April 30, 2025 | msn.comNeuronetics to Announce Q1 2025 Results and Host Live Conference Call on May 6April 24, 2025 | msn.comNeuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference CallApril 22, 2025 | tmcnet.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVCN, NYXH, CERS, and STIM Company DescriptionsCerus NASDAQ:CERS$1.46 +0.02 (+1.03%) As of 10:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.Neovasc NASDAQ:NVCNNeovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.Nyxoah NASDAQ:NYXH$7.92 +0.06 (+0.76%) As of 10:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.Neuronetics NASDAQ:STIM$3.42 +0.05 (+1.48%) As of 10:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Why Centene Stock Dropped 40% — And Whether It's a Buy Now D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
